MedTrace Logo

Dexmedetomidine Infusion Versus Oral Melatonin for Prevention of Intensive Care Delirium

NCT06076668 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2023-10-17

No results posted yet for this study

Summary

This study aims to compare the effect of dexmedetomidine infusion and oral melatonin on preventing delirium in intensive care unit (ICU) patients.

Conditions

  • Dexmedetomidine
  • Melatonin
  • Delirium

Interventions

DRUG

Dexmedetomidine

Patients will receive an intravenous dexmedetomidine infusion of 0.2 mcg/kg/h starting at 9 p.m. The infusion will be halved at 6:00 A.M. and discontinued at 6:15 A.M.

DRUG

Melatonin 3 MG

Patients will receive oral melatonin tablet 3 mg 9:00 p.m.

DRUG

Saline

Patients will receive saline infusion at the same rate of dexmedetomidine infusion and placebo capsule similar to that of melatonin.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-16
Primary Completion
2024-10-20
Completion
2024-10-20

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06076668 on ClinicalTrials.gov